| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addressing the quality of the ESMO-MCBS
|
Del Paggio, J.C.
|
|
|
28 |
6 |
p. 1406
|
artikel
|
| 2 |
Adult weight gain and colorectal adenomas—a systematic review and meta-analysis
|
Schlesinger, S.
|
|
|
28 |
6 |
p. 1217-1229
|
artikel
|
| 3 |
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient
|
Pellegrino, B.
|
|
|
28 |
6 |
p. 1405-1406
|
artikel
|
| 4 |
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
|
Kulke, M.H.
|
|
|
28 |
6 |
p. 1309-1315
|
artikel
|
| 5 |
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
|
Van Cutsem, E.
|
|
|
28 |
6 |
p. 1316-1324
|
artikel
|
| 6 |
A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3)
|
Shamash, J.
|
|
|
28 |
6 |
p. 1333-1338
|
artikel
|
| 7 |
Are ALK rearrangement variants promising predictive biomarker of ALK tyrosine kinase inhibitors efficacy?
|
Duruisseaux, M.
|
|
|
28 |
6 |
p. 1401
|
artikel
|
| 8 |
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
|
Chaput, N.
|
|
|
28 |
6 |
p. 1368-1379
|
artikel
|
| 9 |
Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group
|
Stacchiotti, S.
|
|
|
28 |
6 |
p. 1230-1242
|
artikel
|
| 10 |
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer
|
Lote, H.
|
|
|
28 |
6 |
p. 1243-1249
|
artikel
|
| 11 |
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma
|
Kim, H.R.
|
|
|
28 |
6 |
p. 1250-1259
|
artikel
|
| 12 |
Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment
|
Condorelli, R.
|
|
|
28 |
6 |
p. 1167-1168
|
artikel
|
| 13 |
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
|
Grasselli, J.
|
|
|
28 |
6 |
p. 1294-1301
|
artikel
|
| 14 |
DPD testing must remain a recommended option, but not a recommended routine test
|
Milano, G.
|
|
|
28 |
6 |
p. 1399
|
artikel
|
| 15 |
Editorial board
|
|
|
|
28 |
6 |
p. ii-iii
|
artikel
|
| 16 |
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
|
Guo, J.
|
|
|
28 |
6 |
p. 1380-1387
|
artikel
|
| 17 |
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
|
Knox, J.J.
|
|
|
28 |
6 |
p. 1339-1345
|
artikel
|
| 18 |
Identifying predictive factors of chemotherapy-induced nausea and vomiting (CINV): a novel approach
|
Scotté, F.
|
|
|
28 |
6 |
p. 1165-1167
|
artikel
|
| 19 |
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
|
Barbour, S.
|
|
|
28 |
6 |
p. 1268-1273
|
artikel
|
| 20 |
Networking for ovarian rare tumors: a significant breakthrough improving disease management
|
Chiannilkulchai, N.
|
|
|
28 |
6 |
p. 1274-1279
|
artikel
|
| 21 |
Nivolumab induced radiation recall pneumonitis after two years of radiotherapy
|
Shibaki, R.
|
|
|
28 |
6 |
p. 1404-1405
|
artikel
|
| 22 |
Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial
|
Necchi, A.
|
|
|
28 |
6 |
p. 1346-1351
|
artikel
|
| 23 |
Pembrolizumab associated hemophagocytic lymphohistiocytosis
|
Shah, D.
|
|
|
28 |
6 |
p. 1403
|
artikel
|
| 24 |
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
|
Kang, S.P.
|
|
|
28 |
6 |
p. 1388-1398
|
artikel
|
| 25 |
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
|
Poveda, A.
|
|
|
28 |
6 |
p. 1280-1287
|
artikel
|
| 26 |
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
|
Vidal, J.
|
|
|
28 |
6 |
p. 1325-1332
|
artikel
|
| 27 |
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance)
|
Fuchs, M.A.
|
|
|
28 |
6 |
p. 1359-1367
|
artikel
|
| 28 |
Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study
|
Kataoka, Y.
|
|
|
28 |
6 |
p. 1402
|
artikel
|
| 29 |
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
|
Limkin, E.J.
|
|
|
28 |
6 |
p. 1191-1206
|
artikel
|
| 30 |
Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group
|
Kwakman, J.J.M.
|
|
|
28 |
6 |
p. 1288-1293
|
artikel
|
| 31 |
Reply to the letter to the editor ‘Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study’ by Daly et al.
|
Furlanetto, J.
|
|
|
28 |
6 |
p. 1400
|
artikel
|
| 32 |
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma
|
Bröckelmann, P.J.
|
|
|
28 |
6 |
p. 1352-1358
|
artikel
|
| 33 |
Statistical controversies in clinical research: overlap and errors in the meta-analyses of microRNA genetic association studies in cancers
|
Park, J.H.
|
|
|
28 |
6 |
p. 1169-1182
|
artikel
|
| 34 |
Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials
|
Le-Rademacher, J.
|
|
|
28 |
6 |
p. 1183-1190
|
artikel
|
| 35 |
Table of Contents
|
|
|
|
28 |
6 |
p. iv-vi
|
artikel
|
| 36 |
Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
|
Hierro, C.
|
|
|
28 |
6 |
p. 1207-1216
|
artikel
|
| 37 |
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
|
Dranitsaris, G.
|
|
|
28 |
6 |
p. 1260-1267
|
artikel
|
| 38 |
Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor
|
Siravegna, G.
|
|
|
28 |
6 |
p. 1302-1308
|
artikel
|
| 39 |
Tracking colorectal cancer evolution in time and space
|
Rospo, G.
|
|
|
28 |
6 |
p. 1163-1165
|
artikel
|
Tijdschrift beschrijving